Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature

Purpose to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. Observations ME completely resolved after Intravitreal Dexamethasone Implant (IDI). Conclusions and Importanc...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2024-03, Vol.34 (2), p.NP52-NP55
Main Authors: Maceroni, Martina, Minnella, Angelo Maria
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c292t-3895043eb2c5e23ec932968c9a42ea1d493483c9f402daed67d2794fe6fc7ea63
container_end_page NP55
container_issue 2
container_start_page NP52
container_title European journal of ophthalmology
container_volume 34
creator Maceroni, Martina
Minnella, Angelo Maria
description Purpose to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. Observations ME completely resolved after Intravitreal Dexamethasone Implant (IDI). Conclusions and Importance ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.
doi_str_mv 10.1177/11206721231199120
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_11206721231199120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_11206721231199120</sage_id><sourcerecordid>10.1177_11206721231199120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c292t-3895043eb2c5e23ec932968c9a42ea1d493483c9f402daed67d2794fe6fc7ea63</originalsourceid><addsrcrecordid>eNp9UE1PAjEQbYwmIvoDvPUPLPaLXeqNEPxIMCZGz5uhncqSZUvaLsLRf24J3kw8zbzJvPdmHiG3nI04r6o7zgUrK8GF5FzrDM7IgFdCFSXj5Xnu86g4LlySqxjXjAmmlRiQ7zeMvu1T4zvqHX0B07cQ6NziBmhE4zsL4UCTp6FJ_b7ZwJKCSxho06UAuyYFhJZa3MMG0wqi7_CeTqmBiDTg1odEobMUMtg1-HU0SSukbZM1IPUBr8mFgzbizW8dko-H-fvsqVi8Pj7PpovCCC1SISd6zJTEpTBjFBKNlkKXE6NBCQRulZZqIo12igkLaMvKikorh6UzFUIph4SfdE3wMQZ09Tbkd8Kh5qw-Zlj_yTBzRidOhE-s174PXT7xH8IPOetzhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature</title><source>SAGE</source><creator>Maceroni, Martina ; Minnella, Angelo Maria</creator><creatorcontrib>Maceroni, Martina ; Minnella, Angelo Maria</creatorcontrib><description>Purpose to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. Observations ME completely resolved after Intravitreal Dexamethasone Implant (IDI). Conclusions and Importance ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.</description><identifier>ISSN: 1120-6721</identifier><identifier>EISSN: 1724-6016</identifier><identifier>DOI: 10.1177/11206721231199120</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>European journal of ophthalmology, 2024-03, Vol.34 (2), p.NP52-NP55</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c292t-3895043eb2c5e23ec932968c9a42ea1d493483c9f402daed67d2794fe6fc7ea63</cites><orcidid>0000-0002-3754-7486</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids></links><search><creatorcontrib>Maceroni, Martina</creatorcontrib><creatorcontrib>Minnella, Angelo Maria</creatorcontrib><title>Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature</title><title>European journal of ophthalmology</title><addtitle>European Journal of Ophthalmology</addtitle><description>Purpose to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. Observations ME completely resolved after Intravitreal Dexamethasone Implant (IDI). Conclusions and Importance ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.</description><issn>1120-6721</issn><issn>1724-6016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UE1PAjEQbYwmIvoDvPUPLPaLXeqNEPxIMCZGz5uhncqSZUvaLsLRf24J3kw8zbzJvPdmHiG3nI04r6o7zgUrK8GF5FzrDM7IgFdCFSXj5Xnu86g4LlySqxjXjAmmlRiQ7zeMvu1T4zvqHX0B07cQ6NziBmhE4zsL4UCTp6FJ_b7ZwJKCSxho06UAuyYFhJZa3MMG0wqi7_CeTqmBiDTg1odEobMUMtg1-HU0SSukbZM1IPUBr8mFgzbizW8dko-H-fvsqVi8Pj7PpovCCC1SISd6zJTEpTBjFBKNlkKXE6NBCQRulZZqIo12igkLaMvKikorh6UzFUIph4SfdE3wMQZ09Tbkd8Kh5qw-Zlj_yTBzRidOhE-s174PXT7xH8IPOetzhA</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Maceroni, Martina</creator><creator>Minnella, Angelo Maria</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-3754-7486</orcidid></search><sort><creationdate>202403</creationdate><title>Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature</title><author>Maceroni, Martina ; Minnella, Angelo Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c292t-3895043eb2c5e23ec932968c9a42ea1d493483c9f402daed67d2794fe6fc7ea63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maceroni, Martina</creatorcontrib><creatorcontrib>Minnella, Angelo Maria</creatorcontrib><collection>CrossRef</collection><jtitle>European journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maceroni, Martina</au><au>Minnella, Angelo Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature</atitle><jtitle>European journal of ophthalmology</jtitle><addtitle>European Journal of Ophthalmology</addtitle><date>2024-03</date><risdate>2024</risdate><volume>34</volume><issue>2</issue><spage>NP52</spage><epage>NP55</epage><pages>NP52-NP55</pages><issn>1120-6721</issn><eissn>1724-6016</eissn><abstract>Purpose to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. Observations ME completely resolved after Intravitreal Dexamethasone Implant (IDI). Conclusions and Importance ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/11206721231199120</doi><orcidid>https://orcid.org/0000-0002-3754-7486</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1120-6721
ispartof European journal of ophthalmology, 2024-03, Vol.34 (2), p.NP52-NP55
issn 1120-6721
1724-6016
language eng
recordid cdi_crossref_primary_10_1177_11206721231199120
source SAGE
title Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T22%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resolution%20of%20Macular%20Edema%20secondary%20to%20rituximab%20after%20intravitreal%20dexamethasone:%20A%20case%20report%20and%20a%20review%20of%20the%20literature&rft.jtitle=European%20journal%20of%20ophthalmology&rft.au=Maceroni,%20Martina&rft.date=2024-03&rft.volume=34&rft.issue=2&rft.spage=NP52&rft.epage=NP55&rft.pages=NP52-NP55&rft.issn=1120-6721&rft.eissn=1724-6016&rft_id=info:doi/10.1177/11206721231199120&rft_dat=%3Csage_cross%3E10.1177_11206721231199120%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c292t-3895043eb2c5e23ec932968c9a42ea1d493483c9f402daed67d2794fe6fc7ea63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.1177_11206721231199120&rfr_iscdi=true